Erectile dysfunction in psychiatric patients

2011 ◽  
Vol 26 (S2) ◽  
pp. 1548-1548
Author(s):  
M. Ladea ◽  
M. Bran ◽  
C.M. Barbu ◽  
M.C. Sarpe
Keyword(s):  
Erectile Dysfunction ◽  
Sexual Function ◽  
Antipsychotic Medication ◽  
Sexual Desire ◽  
Erectile Function ◽  
Psychotic Disorders ◽  
Psychiatric Patients ◽  
Young Patients ◽  
Male Sexual Function

IntroductionErectile dysfunction (ED) is defined as the inability to achieve or maintain an erection sufficient for sexual activity.ObjectivesED is a common condition in psychiatric patients, which can modify their quality of life.AimsThe aim of this study is to assess the prevalence and the severity of ED in psychiatric patients.MethodsThis naturalistic, observational study was conducted during a six months period. The International Index of Erectile Function (IIEF) 15-item questionnaire was used to assess 144 male inpatients with different psychiatric disorders. IIEF is a brief, cross-culturally valid, self-administered scale for detecting treatment-related changes in patients with erectile dysfunction and addresses the relevant domains of male sexual function: erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction. The patients were analyzed by age, psychiatric diagnosis, medication, IIEF scores at admission.ResultsThen mean age was 36.4 years. The lot included 44 patients with Psychotic Disorders, 68 with Mood Disorders, 21 with Alcohol Dependence, 11 with Personality Disorders. Severe ED was registered in 38% of investigated patients, which determined abandon of sexual attempts in 57% of cases; 12% had moderate ED, 15% had mild to moderate ED, 18% had mild ED and 17% had normal sexual function. No orgasm was reported in 32% of patients and 37% had no sexual desire. Under treatment with antipsychotic medication 78% had severe or moderate ED.ConclusionsSevere ED was correlated with age, also being seen in young patients. ED was correlated with depression, schizophrenia and antipsychotic medication.

scholarly journals Cross Sectional Survey of Priapism and Sexual Dysfunction in 353 Men with Sickle Cell Disease

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 2302-2302
Author(s):  
Ibrahim Musa Idris ◽  
Jamil Aliyu Galadanci ◽  
Akib Abba ◽  
Sharfuddeen Abbas Mashi ◽  
Anele Uzoma ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Sexual Dysfunction ◽  
Focus Group ◽  
Sexual Function ◽  
Sickle Cell ◽  
Sexual Desire ◽  
Erectile Function ◽  
Clinical Epidemiology ◽  
Cross Sectional ◽  
Significant Difference

Introduction: In both high and low income countries, life span in sickle cell disease (SCD) is increasing and quality of life is improving. Recent research activities have focused on decreasing SCD-related morbidities. However, limited research has been done on clinical epidemiology of priapism, sexual dysfunction and libido in men with SCD. As part of our ongoing Priapism in Nigeria (PIN) cohort to assess knowledge gap in clinical epidemiology of priapism and sexual dysfunction in men with SCD, we tested the hypothesis that sexual dysfunction is high in men with SCD compared to age/race matched men without SCD. Methods: We utilized a mixed method study design (cross-sectional survey and focus group discussions) in men, aged 18-40 years, with confirmed SCD and men without SCD as comparators for the survey. Participants were recruited from the adult sickle cell clinic and general outpatients department of Aminu Kano Teaching Hospital (AKTH) and Murtala Mohammed Specialists Hospital (MMSH) in Kano, Nigeria from February to July 2019. Priapism is defined as a purposeless painful erection, unrelated to sexual desire; and mostly occurs in the stuttering or recurrent ischemic form, which lasts less than 4 hours. We used the validated International Index of Erectile Function (IIEF) questionnaire to assess erectile dysfunction in this population. Additionally, we conducted 6 focus group discussions in Nigeria (3 sessions) and United States (3 sessions), respectively; in which we asked open ended questions about symptoms, experiences, beliefs and life impacts of priapism. Data were presented as means ± standard deviation or proportions with 95% Confidence Intervals. The t-test and Chi square test were used to compare demographic data. Similarly, domain-specific scores, which included: 1) erectile function, 2) sexual desire, 3) orgasmic function, 4) overall satisfaction with sex life, and 5) intercourse satisfaction- were compared between the two groups using t-test; where higher scores indicate better sexual function. Erectile domain was further sub-classified into normal (26-30), mild ED (22-25), mild-moderate ED (17-21), moderate ED (11-16) and severe ED (0-10). We considered alpha level of significance to be <0.05. The focus group data was analyzed using an iterative inductive/deductive approach. Results: A total of 353 men with SCD and 250 men without SCD were evaluated; for the demographic features the only significant difference was in monthly income (p 0.007) with SCD being higher, table 1. The prevalence of any priapism episode (major or stuttering) in men with and without SCD was 31.72% (112 of 353) and 2% (5 of 250). Among men with SCD, 25.9% (29 of 112) and 74.1% (83 of 112) had major and stuttering priapism episodes, respectively. Based on the IIEF, the men with SCD when compared to men without SCD had significantly lower total mean scores (24.9 vs 29.6, p 0.0002), erectile function (9.9 vs 11.5, p 0.005), sexual desire (5.8 vs 7.1, p<0.0001), and overall satisfaction with sex life (2.3 vs 3.5, p<0.0001). No significant difference in orgasmic function (p=0.29) and intercourse satisfaction (p=0.12) was observed. Among the married men with and without SCD, 55% (21 of 38) and 84% (22 of 26) had normal erectile function, and 26.3% (10 of 38) and 11.5% (3 of 26) had severe erectile dysfunction, respectively. Based on the data from our focus groups with a total of 28 and 7 participants (n=35), in Nigeria and United States respectively, we were guided by biopsychosocial and socio-ecological models to develop a conceptual framework (not shown). We identified themes on cultural context, priapism (triggers, schema, episodes and coping strategies), emotional and sexual function impacts, with respective quotes (results not shown). Conclusions: In the largest cross-sectional and qualitative study of priapism in men with SCD to date, we demonstrated that priapism and sexual dysfunction are significant cause of morbidity when compared to men without SCD. Married participants with SCD have 2-fold greater proportion of severe erectile dysfunction than those without SCD. Our qualitative results revealed tremendous impact of priapism and sexual dysfunction in men with SCD. Participants with priapism experience shame, anxiety and depression, and declined sexual function. There was diversity in causal attribution and coping strategies of priapism. Disclosures Idris: Fogarty International Center: Research Funding.

scholarly journals Urinary symptoms and sexual dysfunction among Italian men: The results of the #Controllati survey

2017 ◽  
Vol 89 (1) ◽  
pp. 75
Author(s):  
Vincenzo Mirone ◽  
Roberto Carone ◽  
Giuseppe Carrieri ◽  
Elisabetta Costantini ◽  
Giuseppe Morgia ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Sexual Desire ◽  
Sexual And Reproductive Health ◽  
Premature Ejaculation ◽  
Urinary Symptoms ◽  
Research Approach ◽  
Sexual Disorder ◽  
Increased Risk ◽  
Large Survey

Objective: Prevention may improve the quality of life and sexual and reproductive health. To improve prevention require a comprehensive research approach that examines the frequency and risk factors for urologic conditions. In June 2016 the Italian Urologic Society coordinated a preventive initiative : the 1st Week of Male Urologic Prevention ”#Controllati”. Material and methods: During the 1st Week of Male Urologic Prevention “#Controllati”, men aged 18 years or more were invited to attend participating urologic centers for a free of charge visit for counseling about urologic or andrologic conditions. Each participating man underwent a physical examination. Further he was asked about his a medical history and about his urologic symptoms, sexual activity and possible related problems. Results: Data were collected in 81 centers: 2380 men answered the questionnaire. A total of 1226 subjects participating in the study reported one or more urinary symptom [51.5% (IC 95% 48.9%-54.5%)]. The risk of any urinary symptoms increased with age: in comparison with men aged &lt; = 30 years or less the risk of any urinary symptoms was 2.31, 2.92, 5.12, 7.82 and 17.02 respectively in the class age 31-40, 41-50, 51-60, 61-70 and &gt; = 71. Overweight/obese men were at increased risk of any urinary symptoms [OR1.35 (95% CI 1.12-1.64)]. 27.2% (IC 95% overall 25.2% -29.3%) of the subjects had at least a sexual disorder (erectile dysfunction, premature ejaculation, hypoactive sexual desire). The erectile dysfunction and hypoactive sexual desire increased with age, but premature ejaculation tended to be higher among younger aged men aged 40 years or more. Current any urinary symptoms [OR 1.85 (CI 1.40-2.43)], hypertension [OR 1.66 (95% CI 1.21-2.26) and diabetes (OR 2.37 (95% CI 1.45-3.88)] increased the risk of erectile dysfunction. Conclusions: This large survey gives a picture of the burden of the more frequent urologic conditions offering useful information in order to focus preventive campaign.

scholarly journals PENGARUH SINDROMA DEPRESI TERHADAP DISFUNGSI EREKSI

2013 ◽  
Vol 1 (2) ◽  
Author(s):  
Andre Hutagalung ◽  
Christoffel Elim ◽  
Herdy Munayang
Keyword(s):  
Quality Of Life ◽  
Erectile Dysfunction ◽  
Sexual Function ◽  
Key Words ◽  
Sexual Intercourse ◽  
Social Process ◽  
Sexual Life ◽  
Sexual Stimulus ◽  
Physical Diseases

Abstract: Normal sexual function is a bio-psycho-social process which is significantly related to the quality of life (QOL). Any disturbance in one of the components can be a disaster in sexual life.  Erectile dysfunction is a disability to get an erection or to maintain the erection well enough for a sexual intercourse, which persists or recurs at least three months conse-cutively due to either psychogenic or organic disturbances, or both. Some psychogenic dis-turbances especially depression, anxiety, and relational distress, play some important roles in ED. Besides that, aging, low testoteron level, physical diseases, and some certain medicines have to be included. Key words: erection, erectile dysfunction, sexual stimulus, depression.     Abstract: Fungsi seksual yang normal merupakan suatu proses biopsikososial yang berkaitan langsung dengan kualitas hidup. Adanya gangguan pada salah satu komponen dapat menjadi malapetaka bagi kehidupan seksual. Disfungsi ereksi dapat dedefinisikan sebagai suatu keti-dakmampuan untuk ereksi atau mempertahankan ereksi yang cukup untuk melakukan hu-bungan seksual yang memuaskan, yang menetap atau berulang paling tidak selama tiga bulan berturut-turut. Gangguan psikogenik khususnya sindroma depresi, ankietas, dan distres relasional berperan penting dalam hal terjadinya disfungsi ereksi. Disamping itu usia lanjut, rendahnya kadar testoteron, penyakit fisik, dan beberapa jenis obat perlu diperhitungkan. Kata kunci: fisiologi ereksi, disfungsi ereksi, stimulus seksual, depresi.

scholarly journals Disfungsi ereksi pada penyakit kardiovaskular

2016 ◽  
Vol 8 (1) ◽  
Author(s):  
Nancy Sasube ◽  
Starry H. Rampengan
Keyword(s):  
Quality Of Life ◽  
Cardiovascular Disease ◽  
Erectile Dysfunction ◽  
Sexual Function ◽  
Risk Mitigation ◽  
Time Frame ◽  
Lifestyle Changes ◽  
Cvd Risk ◽  
Adherence To Medication

Abstract: Erectile dysfunction (ED) is common among cardiovascular disease (CVD) patients. It is an important component of the quality of life. Moreover, it also confers an independent risk for future CV events. There is usual a 3-year time frame between the onset of ED symptoms and a CV event which offers an opportunity for risk mitigation. Thus, sexual function should be incorporated into CVD risk assessment for all males. Algorithms for the management of patient with ED have been proposed according to the risk for sexual activity and future (comprising of both lifestyle changes and pharmacological treatment) improve overall vascular health, including sexual function. Proper sexual counselling improves the quality of life and increase adherence to medication. Testosterone assessment may be useful for both diagnosis of ED, risk stratification, and further management. There are issues to be addressed, such as whether PDE5 inhibitors reduce CV risk. Management of ED requires a collaborative approach and the role of the cardiologist is pivotal.Keywords: cardiovascular disease, erectile dysfunction, sexual functionAbstrak: Disfungsi ereksi (DE) umumnya ditemukan pada pasien dengan penyakit kardiovaskular. DE merupakan komponen penting terhadap penurunan kualitas hidup pada laki-laki dan merupakan indikator terhadap risiko kejadian penyakit kardiovaskular di masa depan. Terdapat jangka waktu sekitar 3 tahun antara munculnya DE dan kejadian penyakit kardiovaskular, sehingga masih ada kesempatan untuk mencegah risiko yang akan terjadi. Dengan demikian fungsi seksual harus dimasukkan dalam penilaian risiko penyakit kardiovaskular pada semua laki-laki. Algoritma untuk penanganan pasien DE telah dirumuskan sesuai dengan risiko aktivitas seksual dan kejadian penyakit kardiovaskular di masa depan. Beberapa pendekatan untuk mengurangi resiko penyakit kardiovaskular terdiri dari perubahan gaya hidup dan pengobatan farmakologi dapat meningkatkan kesehatan termasuk fungsi seksual. Konseling seksual yang tepat dapat meningkatkan kualitas hidup dan meningkatkan kepatuhan terhadap pengobatan. Penggunaan testosteron dan inhibitor PDE5 dapat bermanfaat dalam pengobatan DE. Penanganan DE memerlukan kerjasama dari berbagai bidang spesialistik termasuk peran dari kardiologis.Kata kunci: disfungsi ereksi, fungsi seksual, penyakit kardiovaskular

scholarly journals A Prospective Clinical Study of a Prosexual Nutrient: Nano Leo for Evaluation of Libido, Erection, and Orgasm in Indian Men with Erectile Dysfunction

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
S. N. Shankhwar ◽  
A. A. Mahdi ◽  
A. V. Sharma ◽  
Kishan Pv
Keyword(s):  
Erectile Dysfunction ◽  
Erectile Function ◽  
Sperm Count ◽  
Sperm Concentration ◽  
Prospective Clinical Study ◽  
Testosterone Levels ◽  
Seminal Parameters ◽  
Secondary Endpoints ◽  
Indian Men

Aim. The present study aimed to assess the effects of Nano Leo, a prosexual nutrient formulation, on libido, erection, and orgasm in patients with erectile dysfunction (ED). Methods. This was a prospective, single-center, phase IV efficacy study. Patients received two capsules for 7 days and thereafter one capsule through 90 days. Main outcome measures: primary endpoint was change in erectile function assessed using the International Index of Erectile Function (IIEF) questionnaire. Secondary endpoints included improvement in testosterone levels, FSH, LH, and prolactin levels; seminal parameters; and overall quality of life (QoL). Results. Our study included 99 men (mean age 32.2 ± 4.71 years). Mean erectile function domain score increased from 18.9 ± 5.67 at baseline to 23.7 ± 4.01 on day 90 (P<0.001). Similar improvements were observed in orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction domains of IIEF score which was seen as early as day 30. Improved IIEF corroborated with improvement in all QoL domains. From baseline to day 90, treatment with Nano Leo increased testosterone levels (5.04 ± 2.22 vs. 5.57 ± 1.53 ng/mL, P<0.001). Seminal parameters like sperm concentration (44.07 ± 48.28 vs. 56.21 ± 50.45 million/mL) and total sperm count per ejaculate (130.40 ± 156.05 vs. 142.5 ± 161.23 million/mL) significantly increased on day 90 compared to baseline. No changes were observed in hepatic and renal function parameters, and no adverse events were reported which promise the safety of the product, Nano Leo. Conclusion. Nano Leo showed improved libido, erection, and orgasm as evaluated by IIEF and QoL and was well tolerated. Therefore, Nano Leo could be an effective and safe pronutrient supplement in managing ED.

scholarly journals Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels

2016 ◽  
Vol 101 (8) ◽  
pp. 3096-3104 ◽  
Author(s):  
Glenn R. Cunningham ◽  
Alisa J. Stephens-Shields ◽  
Raymond C. Rosen ◽  
Christina Wang ◽  
Shalender Bhasin ◽  
...  
Keyword(s):  
Sexual Function ◽  
Sexual Activity ◽  
Sexual Desire ◽  
Erectile Function ◽  
Controlled Trial ◽  
Older Men ◽  
Threshold Effect ◽  
The United States ◽  
Baseline Characteristics ◽  
Estradiol Levels

Context: The Testosterone Trials are a coordinated set of seven trials to determine the efficacy of T in symptomatic men ≥65 years old with unequivocally low T levels. Initial results of the Sexual Function Trial showed that T improved sexual activity, sexual desire, and erectile function. Objective: To assess the responsiveness of specific sexual activities to T treatment; to relate hormone changes to changes in sexual function; and to determine predictive baseline characteristics and T threshold for sexual outcomes. Design: A placebo-controlled trial. Setting: Twelve academic medical centers in the United States. Participants: A total of 470 men ≥65 years of age with low libido, average T &lt;275 ng/dL, and a partner willing to have sexual intercourse at least twice a month. Methods: Men were assigned to take T gel or placebo for 1 year. Sexual function was assessed by three questionnaires every 3 months: the Psychosexual Daily Questionnaire, the Derogatis Interview for Sexual Function, and the International Index of Erectile Function. Results: Compared with placebo, T administration significantly improved 10 of 12 measures of sexual activity. Incremental increases in total and free T and estradiol levels were associated with improvements in sexual activity and desire, but not erectile function. No threshold T level was observed for any outcome, and none of the 27 baseline characteristics predicted responsiveness to T. Conclusions: In older men with low libido and low T levels, improvements in sexual desire and activity in response to T treatment were related to the magnitude of increases in T and estradiol levels, but there was no clear evidence of a threshold effect.

scholarly journals P759 Correlation of quality-of-life components with sexual function scores and disease duration in patients with inflammatory bowel disease

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S605-S605
Author(s):  
V Domislović ◽  
M Brinar ◽  
L Vujičić ◽  
M Novosel ◽  
D Grgić ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Sexual Function ◽  
Erectile Function ◽  
Disease Duration ◽  
Function Score ◽  
Validated Questionnaire ◽  
Inflammatory Bowel ◽  
Male Patients ◽  
The Impact

Abstract Background Inflammatory Bowel Disease (IBD) has a negative impact on quality of life (QOL), and sexuality is one of its major determinants. The impact of disease characteristics on sexuality and intimacy is one of the main concerns of IBD patients. Despite the obvious relevance of this problem, knowledge of the extent and the determinants of sexual dysfunction in persons with IBD is limited. The main goal of the study was to determine the correlation of quality of life (QOL) and it’s components in patients with IBD, and to investigate the impact of disease duration on QOL components. Methods In this cross-sectional study patients fulfilled anonymous validated questionnaire on their sexual function. In International Index of Erectile Function (IIEF) for males, five domains were evaluated through questions on erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall satisfaction. In women were six domains assessed, desire, arousal, lubrication, orgasmic function, satisfaction and pain. For both scores, higher scores indicated a better function. Patients also fulfilled IBDQ-32, a validated questionnaire for assessing quality of life in IBD patients that consists of four main components (social, emotional, systemic and bowel function). Results In this study we have enrolled 202 patients who fulfilled the questionnaire (133 CD, 69 UC). Among them 122 were men and 80 women. Average age of included patients was 39.2 ± 11.02. Prevalence of SD in women was 70% (n = 60) and 18% (n = 22) in males. Female patients with sexual dysfunction had lower emotional and social QOL (p = 0.035 and p = 0.03, respectively). Total male IIEF sexual function score correlated significantly with all of the components of IBDQ; emotional (rho=0.36, p &lt; 0.001) systemic (rho=0.24, p = 0.006), social (rho=0.28, p = 0.002), bowel (rho=0.27, p = 0.002) and with total IBDQ (rho=0.36, p &lt; 0.001). Regarding erectile function score, there was also correlation with all of the components of IBDQ. Total female sexual function FSFI score correlated significantly only with systemic component of IBDQ (rho=0.25, p = 0.02). Interestingly, in male patients disease duration correlate negatively with emotional and social component of IBDQ (rho = −0.21, p = 0.02 and rho=-023, p = 0.01, respectively), which was not the case in female patients. Conclusion The results show correlation of sexual function score with components of QOL, which were more correlated in male patients. Our results suggest that longer disease duration might have positive impact on emotional and social life in male patients, which could be connected with achieving disease control and accepting the disease. It is important to provide proper psychological support, medical treatment and educational information.

Sign in / Sign up

Export Citation Format

Share Document